EPICEL AU201

MAUDE Adverse Event Report

MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed from a company representative,health report with the FDA on 2017-11-02 for EPICEL AU201 manufactured by Vericel Corporation.

Event Text Entries

[90900552] Total number of grafts: 144.
Patient Sequence No: 1, Text Type: N, H10


[90900553] This spontaneous report was received from a physician via a customer care representative on 06-oct-2017, concerning a (b)(6) male patient- (b)(6) who expired after being grafted with cultured epidermal autografts (epicel). The patient was grafted with 144 units of epicel with lot number ee01842 for 90% total body surface area (tbsa) full thickness burns. The relevant medical history included 90% total body surface thermal burns. Concomitant medication details were not reported. Allergies were ruled out to vancomycin, amikacin and amphotericin b. No other significant dermatology history reported. On (b)(6) 2014, the patient was injured and was hospitalized with 90% tbsa burn. On (b)(6) 2014 at 12:00 am, the biopsy was harvested from left groin and left lower abdomen. The patient had microbial wound infection (stenotrophomonas maltophilia, enterobacter cloacae, and klebsiella pneumoniae). It was reported that the patient underwent three grafting surgeries, i. E. On (b)(6) 2014 and in each time he was grafted with 48 units (a total of 144 grafts) of cultured epidermal autografts with lot numbers ee01842, ee01842a and ee01842b, respectively, for 90% tbsa full thickness burns. The product part number was au201 and the sale order number was not reported. Qc sterility test results of the pre-release sample and of final product sample type passed the quality control lot release assays. On 12-oct-2017, the quality control assay was reviewed which included qc2-027 graft inspection, qc2-094 dual stain, and qc2-010 endotoxin and these were interpreted as passed. The personnel monitoring of manufacturing passed in grade a and b parameters. The personnel monitoring of qc sterility passed in grade a parameters. On (b)(6) 2015, the patient expired due to an unspecified reason. Further details including description of clinical presentations, signs, symptoms, diagnostic tests, and baseline data, diagnosis, and autopsy results were not provided. The outcome was fatal. Action taken with epicel was not applicable. The reporter did not provide the causal relationship between death and epicel. Based on the limited information available on the possible cause of death, the company assessed the event of death as possibly related to epicel. Event will be reassessed on receipt of follow up information.
Patient Sequence No: 1, Text Type: D, B5


MAUDE Entry Details

Report Number1226230-2017-00009
MDR Report Key6996783
Report SourceCOMPANY REPRESENTATIVE,HEALTH
Date Received2017-11-02
Date of Report2017-10-06
Date of Event2015-06-14
Date Mfgr Received2017-10-06
Date Added to Maude2017-11-02
Event Key0
Report Source CodeManufacturer report
Manufacturer LinkY
Number of Patients in Event0
Adverse Event Flag3
Product Problem Flag0
Reprocessed and Reused Flag3
Health Professional3
Initial Report to FDA3
Report to FDA3
Event Location3
Manufacturer ContactMS. LIZ GREKAS
Manufacturer Street64 SIDNEY STREET
Manufacturer CityCAMBRIDGE MA 02139
Manufacturer CountryUS
Manufacturer Postal02139
Manufacturer Phone6175885623
Manufacturer G1VERICEL CORPORATION
Manufacturer Street64 SIDNEY STREET
Manufacturer CityCAMBRIDGE MA 02139
Manufacturer CountryUS
Manufacturer Postal Code02139
Single Use3
Previous Use Code3
Event Type3
Type of Report3

Device Details

Brand NameEPICEL
Generic NameCULTURED EPIDERMAL AUTOGRAFTS (EPICEL)
Product CodeOCE
Date Received2017-11-02
Model NumberAU201
Lot NumberEE01842
Device Expiration Date2015-06-14
Device Availability*
Device Eval'ed by Mfgr*
Device Sequence No1
Device Event Key0
ManufacturerVERICEL CORPORATION
Manufacturer AddressVERICEL CORPORATION 64 SIDNEY STREET CAMBRIDGE MA 02139 US 02139


Patients

Patient NumberTreatmentOutcomeDate
101. Death 2017-11-02

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.